Growth Hormone Adding to Controlled Ovarian Hyperstimulation for Improving Embryo Quality
Infertility,Female
About this trial
This is an interventional treatment trial for Infertility,Female focused on measuring Infertility,Female, Embryo Development
Eligibility Criteria
Inclusion Criteria:
- 1)infertility women whose age ≥20 and ≤39 years old; 2)women has done IVF/ICSI assisted treatment ≥1 times; 3)number of IVF/ICSI assisted treatment cylces with ≥6 oocytes retrieved ≥1; 4)number of IVF/ICSI assisted treatment cylces with ≥50% fertilization rate ≥1 ; 5)historical assisted reproduction cycles without ≥6C-Ⅱ level embryos at the third day after oocytes retrieval or without blastocyst formation after blastocyst culturing.
Exclusion Criteria:
- 1) Diseases related to IVF treatment outcome, such as untreated hydrosalpinx, uterine fibroids affecting uterine cavity, myometriosis, endometrial lesions, obvious uterine abnormalities,etc; 2)Severe acute or chronic liver or kidney diseases, such as cirrhosis, acute or chronic renal failure, hepatitis B virus activity period,etc.;in patients with abnormal liver and kidney function, the AST or ALT detection value was 2.5 times higher than the upper limit of normal, and the serum creatinine was 2 times higher than the upper limit of normal.
3)Endocrine and metabolic diseases and adrenal diseases, such as diabetes, Cushing's syndrome,etc.; 4)People has allergy history of growth hormone product; 5)Participating in other clinical research; 6)Other conditions that researchers determined not fit to be enrolled.
Sites / Locations
- Reproductive & Genetic Hospital of CITIC-XIANGYARecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
GH group
control group
Growth Hormone adding to controlled ovarian hyperstimulation
regular controlled ovarian hyperstimulation